Sarcoma / 2012 / Article / Tab 2 / Clinical Study
Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study Table 2 Patient characteristics.
(100%)Gender, N (%) Female 68 (58.6%) Histology, N (%) Soft tissue sarcoma 96 (82.8%) Leiomyosarcoma 38 (32.8%) Liposarcoma 23 (19.8%) Synovial sarcoma 14 (12.1%) Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma 21 (18.1%) Bone sarcoma 20 (17.2%) Osteosarcoma 8 (6.9%) Ewing’s sarcoma 12 (10.3%) Site , N (%) Extremity 41 (35.3%) Retroperitoneum 19 (16.4%) Superficial trunk and chest wall 5 (4.3%) Head and neck 2 (1.7%) Cutaneous 1 (0.9%) Visceral non-GI 12 (10.3%) Visceral GI 2 (1.7%) Knee 1 (0.9%) Hip 0 Shoulder 1 (0.9%) Pelvis 4 (3.5%) Femur/humerus 2 (1.8%) Ribs 0 Other 24 (20.7%) Missing 2 (1.7%) Site of metastases, N (%) CNS 1 (0.6%) Lung 74 (44.6%) Liver 24 (14.5%) Soft tissue 11 (6.6%) Locoregional 28 (16.9%) Other 25 (15.1%) Missing 3 (1.8%) Receiving chemotherapy, N (%) Yes 73 (62.9%) Number of sites of metastases Mean (SD) 1.4 (0.7) Minimum, maximum 1, 3 Age at sarcoma diagnosis Mean (SD) 47.7 (17.2) Minimum, maximum 13.6, 83.7 Age at metastatic disease diagnosis Mean (SD) 49.5 (17.1) Minimum, maximum 16.1, 83.8 Age at attainment of current response status Mean (SD) 51.6 (17) Minimum, maximum 18.5, 84.3